IVVD · Invivyd, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $58.37M | $53.43M | $25.38M | $0 | — | — | |
| $78.19M | $38.31M | $137.25M | $158.66M | $179.21M | $182.89M | |
| $88.17M | $66.93M | $63.39M | $49.13M | $47.04M | $36.52M | |
| — | $108.99M | $202.26M | $212.76M | $248.03M | $226.91M | |
| $170.9M | $108.99M | $202.26M | $212.76M | — | — | |
| -$112.53M | -$55.56M | -$176.88M | -$212.76M | -$248.03M | -$226.91M | |
| — | -103.99% | -696.8% | — | — | — | |
| $5.2M | $3.07M | $6.95M | $14.12M | $6.71M | $118K | |
| $0 | $0 | $0 | $0 | $0 | $0 | |
| -$107.33M | -$52.49M | -$169.93M | -$198.64M | -$241.32M | -$226.79M | |
| — | -98.25% | -669.42% | — | — | — | |
| -$107.33M | -$52.53M | -$169.92M | -$198.38M | -$241.58M | -$226.8M | |
| USD/shares | -$0.31 | -$0.30 | -$1.43 | -$1.81 | -$2.23 | -$5.32 |
| USD/shares | -$0.31 | -$0.30 | -$1.43 | -$1.81 | -$2.23 | -$5.32 |
| shares | — | 172.21M | 118.56M | 109.53M | 108.27M | 42.62M |
| shares | — | 172.21M | 118.56M | 109.53M | 108.27M | 42.62M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2024: $5000 in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 314 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Product | $53,426,000 | $25,384,000 | $0 |